JPRN-UMIN000002025
Completed
Phase 2
Clinical study for the first relapsed ALL in children. JPLSG ALL-R08-II: Multicenter phase II clinical trial for children with non-T-ALL in intermediate risk group stratified by the minimal residual disease (MRD). - Multicenter phase II clinical trial for children with relapsed non-T-ALL in intermediate risk group stratified by MRD(JPLSG ALL-R08-II)
Japanese Peditric Leukemia/Lymphoma Study Group(JPLSG)0 sites69 target enrollmentJune 1, 2009
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- first relapsed acute lymphoblastic leukemia in children
- Sponsor
- Japanese Peditric Leukemia/Lymphoma Study Group(JPLSG)
- Enrollment
- 69
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients with mature B\-ALL, Ph positive ALL or MLL rearrangement positive ALL. 2\. Down syndrome 3\. Have any severe bleeding in CNS system. 4\. Have an uncontrolled systemic infection. 5\. Are pregnant or lactating. 6\. Have received a HSCT or organ transplantation. 7\. Have a congenital or aquired immunodifficiency syndrome. 8\. Patients can not be treated with one or more drugs in the protocol.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinical study for the first relapsed ALL in children. JPLSG ALL-R08-I: Prospective observational studyfirst relapsed acute lymphoblastic leukemia in childrenJPRN-UMIN000002026Japanese Peditric Leukemia/Lymphoma Study Group88
Active, not recruiting
Phase 1
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10063621Term: Acute lymphoblastic leukaemia recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001991-31-ATovartis Pharma AG80
Active, not recruiting
Phase 1
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with arecurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10063621Term: Acute lymphoblastic leukaemia recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001991-31-ITOVARTIS PHARMA AG74
Active, not recruiting
Phase 1
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 20.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10063621Term: Acute lymphoblastic leukaemia recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001991-31-BEovartis Pharma AG55
Active, not recruiting
Phase 1
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 20.0 Level: LLT Classification code 10063625 Term: Acute lymphoblastic leukemia recurrent System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10063621 Term: Acute lymphoblastic leukaemia recurrent System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001991-31-DEovartis Pharma AG70